Medicinal Chemistry Research
(TNF-α) levels, but the obtained compounds may be useful
in the induction and maintenance of remission of moderate
to severe UC.
Christophi GP, Rengarajan A, Ciorba MA (2016) Rectal budesonide
and mesalamine formulations in active ulcerative proctosigmoi-
ditis: efficacy, tolerance, and treatment approach. Clin Exp Gas-
troenterol 9:125–130
Danese S, Colombel JF, Peyrin‐Biroulet L, Rutgeerts P, Reinisch W
(2013) Review article: the role of anti‐TNF in the management of
ulcerative colitis–past, present and future. Aliment Pharmacol
Ther 37:855–866
Acknowledgements The authors would like to thank the Brazilian
Research Foundation FAPESP Process 2014/08728-6 for financial
support.
Dinsen S, Baslund B, Klose M, Rasmussen AK, Friis-Hansen L,
Hilsted L, Feldt-Rasmussen U (2013) Why glucocorticoid with-
drawal may sometimes be as dangerous as the treatment itself.
Eur J Intern Med 24:714–720
Fabia R, Willén R, Ar’rajab A, Andersson R, Ahrén B, Bengmark S
(1992) Acetic acid-induced colitis in the rat: a reproducible
experimental model for acute ulcerative colitis. Eur Surg Res
24:211–225
Fumery M, Dulai OS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn
WJ, Singh S (2017) Incidence, risk factors, and outcomes of
colorectal cancer in patients with ulcerative colitis with low-grade
dysplasia: a systematic review and meta-analysis. Clin Gastro-
enterol Hepatol 15:665–674
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K,
Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, Sousa
HT, Dignass A, Carbonnel F (2017) Third European evidence-
based consensus on diagnosis and management of ulcerative
colitis. Part 2: current management. J Crohns Colitis 11:769–784
Marquez Ruiz JF, Kedziora K, Pigott M, Keogh B, Windle H, Gavin J,
Kelleher DP, Gilmer JF (2013) A nitrophenyl-based prodrug type
for colorectal targeting of prednisolone, budesonide and cel-
ecoxib. Bioorg Med Chem Lett 23:1693–1698
Mohamed SS, El-Hadi AA, Abo-Zied KM (2017) Biotransformation
of prednisolone to hydroxy derivatives by Penicillium aur-
antiacum. Biocatal Biotransform 35:215–222
Naganuma M, Aoyama N, Suzuki Y, Nishino H, Kobayashi K, Hirai
F, Watanabe K, Hibi T (2016) Twice-daily budesonide 2-mg
foam induces complete mucosal healing in patients with distal
ulcerative colitis. J Crohns Colitis 10:828–836
O’Donnell S, O’Morain CA (2010) Therapeutic benefits of budesonide
in gastroenterology. Ther Adv Chronic Dis 1:177–186
Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS (2016)
Long-term side effects of glucocorticoids. Expert Opin Drug Saf
15:457–465
Pandit B, Hu Z, Chettiar SN, Zink J, Xiao Z, Etter JP, Bhasin D, Li PK
(2013) Structure-activity relationship studies of thalidomide
analogs with a taxol-like mode of action. Bioorg Med Chem Lett
23:6902–6904
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval The experiment and all the procedures were pre-
viously approved by the Research Ethics Committee of Animal
Experimentation of the School of Pharmaceutical Sciences of Arara-
quara, São Paulo, Brazil (CEUA/FCFAr), under no. 11/2016. All
procedures performed in studies involving animals were in accordance
with the ethical standards of the institution or practice at which the
studies were conducted.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
Alanazi AM, El-Azab AS, Al-Suwaidan IA, ElTahir KEH, Asiri YA,
Abdel-Aziz NI, Alaa AM (2015) Structure-based design of
phthalimide derivatives as potential cyclooxygenase-2 (COX-2)
inhibitors: anti-inflammatory and analgesic activities. Eur J Med
Chem 92:115–123
Ambrożak A, Steinebach C, Gardner ER, Beedie SL, Schnakenburg G,
Figg WD, Gütschow M (2016) Synthesis and antiangiogenic
properties of tetrafluorophthalimido and tetrafluorobenzamido
barbituric acids. ChemMedChem 11:2621–2629
Ananthakrishnan AN, Xavier RJ, Podolsky DK (2017) Corticoster-
oids. In: Inflammatory bowel diseases: a clinician’s guide. John
Wiley & Sons Ltd, Chichester, pp 75–83
Awaad AS, El-Meligy RM, Soliman GA (2013) Natural products in
treatment of ulcerative colitis and peptic ulcer. J Saudi Chem Soc
17:101–124
Bach DH, Liu JY, Kim WK, Hong JY, Park SH, Kim D, Qin SN, Luu
TTT, Park HJ, Xu YN, Lee SK (2017) Synthesis and biological
activity of new phthalimides as potential anti-inflammatory
agents. Bioorg Med Chem 25:3396–3405
Radin M, Sciascia S, Roccatello D, Cuadrado MJ (2017) Infliximab
biosimilars in the treatment of inflammatory bowel diseases: a
systematic review. BioDrugs 31:37–49
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW (2017) Long-
term systemic corticosteroid exposure: a systematic literature
review. Clin Ther 39:2216–2229
Barenholz Y, Gabizon AA, Avnir Y (2015) Liposomal compositions of
glucocorticoid and glucocorticoid derivatives. US Patent 8932627
Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, Figg
WD, Vargesson N (2016) In vivo screening and discovery of
novel candidate thalidomide analogs in the zebrafish embryo and
chicken embryo model systems. Oncotarget 7:33237–33245
Bhat MA, Al-omar MA, Ansari MA, Zoheir KM, Imam F, Attia SM,
Bakheet SA, Nadeem A, Korashy HM, Voronkov A, Berishvili V,
Ahmad SF (2015) Design and synthesis of n-arylphthalimides as
inhibitors of glucocorticoid-induced TNF receptor-related protein,
proinflammatory mediators, and cytokines in carrageenan-induced
lung inflammation. J Med Chem 58:8850–8867
Billmeier U, Dieterich W, Neurath MF, Atreya R (2016) Molecular
mechanism of action of anti-tumor necrosis factor antibodies in
inflammatory bowel diseases. World J Gastroenterol 22:9300–9313
Casal JJ, Bollini M, Lombardo ME, Bruno AM (2016) Thalidomide
analogues: tumor necrosis factor-alpha inhibitors and their eva-
luation as anti-inflammatory agents. Eur J Pharm Sci 83:114–119
Rogler G (2014) Chronic ulcerative colitis and colorectal cancer.
Cancer Lett 345:235–241
Santos JL, Chung MC (2013) Processo de obtenção de compostos
derivados derivados de anti-inflamatórios esteróides (aies), com-
posições farmacêuticas contendo tais compostos e seus usos no
tratamento de doenças de caráter inflamatório. PI 110005943
Seguro LPC, Rosario C, Shoenfeld Y (2013) Long-term complications
of past glucocorticoid use. Autoimmun Rev 12:629–632
Sidoroff M, Kolho KL (2014) Screening for adrenal suppression in
children with inflammatory bowel disease discontinuing gluco-
corticoid therapy. BMC Gastroenterol 14:51
Stidham RW, Lee TCH, Higgins PDR, Deshpande AR, Sussman DA,
Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK (2014)
Systematic review with network meta‐analysis: the efficacy of